BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:691. [PMID: 34358117 DOI: 10.3390/ph14070691] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Lai M, De Carli A, Filipponi C, Iacono E, La Rocca V, Lottini G, Piazza CR, Quaranta P, Sidoti M, Pistello M, Freer G. Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes. Antiviral Res 2022;206:105398. [PMID: 35985406 DOI: 10.1016/j.antiviral.2022.105398] [Reference Citation Analysis]
2 Loas G, Van de Borne P, Darquennes G, Le Corre P. Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension. Pharmaceuticals (Basel) 2022;15:380. [PMID: 35337177 DOI: 10.3390/ph15030380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Le Corre P, Loas G. Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection. Front Pharmacol 2022;13:849095. [DOI: 10.3389/fphar.2022.849095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mühle C, Kremer A, Vetter M, Schmid J, Achenbach S, Schumacher F, Lenz B, Cougoule C, Hoertel N, Carpinteiro A, Gulbins E, Kleuser B, Kornhuber J. COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase.. [DOI: 10.1101/2022.01.19.22269391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abusukhun M, Winkler MS, Pöhlmann S, Moerer O, Meissner K, Tampe B, Hofmann-Winkler H, Bauer M, Gräler MH, Claus RA. Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies. Front Immunol 2021;12:784989. [PMID: 34987511 DOI: 10.3389/fimmu.2021.784989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry 2022. [PMID: 34997196 DOI: 10.1038/s41380-021-01432-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 22.0] [Reference Citation Analysis]
7 Le Corre P, Loas G. Compatibility of FIASMA Pharmacokinetics With Study End Points? Clin Pharmacol Ther 2021. [PMID: 34719015 DOI: 10.1002/cpt.2442] [Reference Citation Analysis]
8 Breiden B, Sandhoff K. Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism. Int J Mol Sci 2021;22:9001. [PMID: 34445706 DOI: 10.3390/ijms22169001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]